ePRO provider Symfo will now offer technology transfer capabilities with its new product Artist. This new product is a user-friendly tool that allows customers to build and deploy their own ePRO studies on demand.
Users have the option to start with Symfo's full-service offering and migrate to Artist when ready, or to begin using it from the very first study. Artist was designed with simplicity in mind to benefit Data Managers, CRAs, and Clinical Assistants. Programming skills are not necessary and a basic knowledge of the MS Office suite is sufficient, according to the company.
Artist may be accessed locally or through an Internet connection. Designers start by defining the general parameters such as name and languages of the study using a configuration panel. The next step is to design each PDA screen with edit checks and logic. Artist offers a drag and drop interface that is intended to make this step straightforward, including importing translations if necessary. Once all designing is completed, users have the ability to test the application in a built-in emulator. The application is then installed on the PDAs and will launch automatically.
Artist is available on a subscription pay-as-you-go basis, either as a stand-alone product or as part of a turn-key bundled package. Visit the company's Web site for more information on this product, www.symfo.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.